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Abstract
Insomnia is a worldwide problem with substantial deleterious health effects. Twin studies have 
shown a heritable basis for various sleep-related traits, including insomnia, but robust genetic risk 
variants have just recently begun to be identified. We conducted genome-wide association studies 
(GWAS) of soldiers in the Army Study To Assess Risk and Resilience in Servicemembers 
(STARRS). GWAS were carried out separately for each ancestral group (EUR, AFR, LAT) using 
logistic regression for each of the STARRS component studies (including 3,237 cases and 14,414 
controls), and then meta-analysis was conducted across studies and ancestral groups. Heritability 
(SNP-based) for lifetime insomnia disorder was significant (h2g=0.115, p=1.78×10−4 in EUR). A 
meta-analysis including three ancestral groups and three study cohorts revealed a genome-wide 
significant locus on Chr 7 (q11.22) (top SNP rs186736700, OR = 0.607, p = 4.88×10−9) and a 
genome-wide significant gene-based association (p = 7.61×10−7) in EUR for RFX3 on Chr 9. 
Polygenic risk for sleeplessness/insomnia severity in UK Biobank was significantly positively 
associated with likelihood of insomnia disorder in STARRS. Genetic contributions to insomnia 
disorder in STARRS were significantly positively correlated with major depressive disorder (rg = 
0.44, se = 0.22, p = 0.047) and type 2 diabetes (rg = 0.43, se = 0.20, p = 0.037), and negatively 
with morningness chronotype (rg = −0.34, se = 0.17, p = 0.039) and subjective well-being (rg = 
−0.59, se = 0.23, p = 0.009) in external datasets. Insomnia associated loci may contribute to the 
genetic risk underlying a range of health conditions including psychiatric disorders and metabolic 
disease.
INTRODUCTION
Insomnia is highly prevalent, affecting 10–20% of adults in the United States1 and 
worldwide.2 The prevalence of insomnia is even higher (~25–50%) among military veterans, 
for whom it is frequently associated with mental health complications and functional 
impairment.3–5 At the population level, insomnia is an important contributor to poor 
perceived health and disability, and healthcare utilization.1, 6 Furthermore, chronic insomnia 
is associated with a multitude of adverse long-term health outcomes, including 
cardiovascular and metabolic disturbances (such as type 2 diabetes) as well as myriad 
mental health problems, including posttraumatic stress disorder (PTSD) and suicide.7–11
Twin studies show that there is a heritable basis to sleep characteristics and insomnia.12–16 
Whereas there have been several recent genome-wide association studies (GWAS) for usual 
sleep duration,17, 18 including a now-replicated locus at PAX8,19 specific genetic risk 
variants for insomnia are just now being identified at genome-wide significance.20–22 Given 
the tremendous variability in causes of insomnia as a symptom, as well as heterogeneity in 
insomnia as a disorder, it is important to fully specify the phenotype(s) under consideration 
in insomnia studies. Better understanding of the molecular bases for insomnia will be critical 
for the development of new treatments.23–25 These efforts will benefit from careful 
consideration of the heterogeneity in insomnia at the phenotypic levels in different groups 
(e.g., causes of insomnia in young versus older cohorts) with the expectation that genetic 
risk factors may differ across populations.
Stein et al. Page 2
Mol Psychiatry. Author manuscript; available in PMC 2018 December 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The purpose of the present study is to use GWAS to elucidate the genetic architecture of 
insomnia. To achieve this aim we employed survey and genome-wide genetic data from the 
Army Study To Assess Risk and Resilience in Servicemembers (STARRS) to determine the 
association between insomnia disorder (approximating DSM-5 criteria) and specific genetic 
risk variants. In so doing, we also looked for consistency of our results with those of a large 
recently published study of sleep disturbance traits in the UK Biobank that included 
insomnia symptoms21 and an even more recently published analysis of a largely overlapping 
UK Biobank sample where a different phenotyping algorithm was used to assign case-
control status based on insomnia symptoms.22 We also determined the extent to which a 
polygenic risk score for insomnia severity, derived from the largest UK Biobank sample 
currently available (http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-
phenotypes-for-337000-samples-in-the-uk-biobank), was significantly associated with 
insomnia disorder in STARRS. Lastly, we determined the heritability of insomnia disorder in 
this generally young and mostly male sample, and explored its genetic relationship to other 
mental and physical health related phenotypes by referencing other publicly available 
GWAS data for those traits.26
METHODS
Subjects
Information in detail about the design and methodology of STARRS can be obtained in our 
prior report.27 Each of the participating institutions approved the human subjects and data 
protection procedures used in the study. As described below, the analyses presented here 
involved two large components of STARRS.
New Soldier Study (NSS)—New soldiers took part in the NSS at the beginning of their 
basic training, which took place between April 2011 and November 2012 at one of three 
Army installations. 39,784 soldiers completed a computerized self-administered 
questionnaire (SAQ, described below) and, of these, 33,088 (83.2%) gave blood samples for 
DNA. The first half of the cohort had samples selected to enrich for probable cases of PTSD, 
suicidality, generalized anxiety disorder, and major depression; and controls with none of 
these disorders were also selected) (NSS1; N = 7,999). A subset of samples from the second 
half of the cohort was subsequently selected for genotyping to include cases of PTSD, 
suicidal behaviors and controls (NSS2; N = 2,835).
Pre/Post Deployment Survey (PPDS)—US Army soldiers from three Brigade Combat 
Teams (BCTs) participated in the PPDS (N = 7,927 eligible soldiers were genotyped) which 
began in the first quarter of 2012. The data included in this report were collected at baseline 
(T0) 4–6weeks prior to deployment to Afghanistan.
Demographics
The population, sex and age composition of our analyzed samples are shown in Table 1. As 
expected, the PPDS subjects were older than the new Army recruits in the NSS. Lifetime 
prevalence estimates (with standard errors) of insomnia disorder are also shown.
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Measures
One of the Composite International Diagnostic Interview screening scales (CIDI-SC)28 was 
used to determine criteria for major depression. The reliable and valid Brief Insomnia 
Questionnaire 29 was used to approximate DSM-5 criteria (which differ immaterially from 
DSM-IV criteria) for Insomnia Disorder. The stem question for insomnia was “Did you ever 
in your life have insomnia - that is, problems either getting to sleep, staying asleep, waking 
too early, or feeling so tired even after a full night’s sleep that it interfered with your daytime 
activities?” Respondents who answered yes were asked “Did you ever in your life have a 
whole month or longer when you had insomnia at least three nights a week?” Respondents 
who answered yes were asked 5 questions introduced with “Think of a typical month when 
your insomnia was worst. During that month, how much did your insomnia interfere with 
your daytime functioning in the following ways”: (1) daytime fatigue, sleepiness, or low 
motivation, (2) headaches, upset stomach, diarrhea or constipation, (3) moodiness 
(irritability, nerves, worry, or depression), (4) reduced performance at work or school, and 
(5) accident proneness. Insomnia Disorder was defined as at least one month of insomnia 
and reporting of at least “Some of the Time” on one or more of these five symptom items. 
Controls were defined as failing to meet the definition of Insomnia Disorder.
DNA Genotyping, Imputation and Population Stratification Adjustment
Detailed information on genotyping, genotype imputation, population assignment and 
principal component analysis for population stratification adjustment are included in our 
previous report30 and in Supplementary Materials. Whole blood samples were shipped to 
Rutgers University Cell & DNA Repository (RUCDR), where they were frozen for later 
DNA extraction using standard methods. NSS1 and PPDS samples were genotyped using the 
Illumina OmniExpress + Exome array with additional custom content (N SNP = 967,537). 
NSS2 samples were genotyped on the Illumina PsychChip (N SNP = 571,054; 477,757 
SNPs overlap with OmniExpress + Exome array).
Relatedness testing was carried out with PLINK v1.9031, 32 and pairs of subjects with π of 
>0.2 were identified, randomly retaining one member of each relative pair. We used a two-
step pre-phasing/imputation approach for genotype imputation, with reference to the 1000 
Genomes Project multi-ethnic panel (August 2012 phase 1 integrated release; 2,186 phased 
haplotypes with 40,318,245 variants). We removed SNPs that were not present in the 1000 
Genomes Project reference panel, had non-matching alleles to 1000 Genome Project 
reference, or had ambiguous, unresolvable alleles (AT/GC SNPs with minor allele frequency 
[MAF] > 0.1). For the Illumina OmniExpress array 664,457 SNPs and for the Illumina 
PsychChip 360,704 SNPs entered the imputation procedure.
Given the ancestral heterogeneity of the STARRS subjects, samples were assigned into 
major population groups (European [EUR], African [AFR] or Latino [LAT]) (see 
Supplementary Materials; also see 30). An Asian [ASI] group that was too small for separate 
analysis was excluded. PCs within each population group were then obtained for population 
stratification adjustment (see also Supplementary Figures 1–3). For quality control (QC) 
purposes we kept autosomal SNPs with missing rate < 0.05; kept samples with individual-
wise missing rate < 0.02; and kept SNPs with missing rate < 0.02. After QC, we merged our 
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study samples with HapMap3 samples. We kept SNPs with minor allele frequency (MAF) > 
0.05 and LD pruned at R2 > 0.05. In order to avoid long range LD structure from interfering 
with the PCA analysis, we excluded SNPs in the MHC region (Chr 6:25–35Mb) and Chr 8 
inversion (Chr 8:7–13Mb).
Statistical Analysis
We used LD score regression (LDSR)33 and GCTA34 with imputed data (modified from 
35, 36) to estimate the proportion of variance in insomnia explained by common SNPs (i.e., 
SNP-heritability, h2g). We estimated h2g of insomnia in EUR with linear mixed models 
implemented in GCTA software, adjusted for 10 PCs and study.
We used PLINK v1.9031, 32 to conduct genome-wide association tests for insomnia disorder 
on imputed SNP dosage with logistic regression adjusted for age, sex, and the top 10 within-
population principal components (PCs). We also conducted sensitivity analyses adjusting for 
lifetime major depressive disorder, of which insomnia is a common symptom. We filtered 
out SNPs with MAF < 0.01 or imputation quality score (INFO) < 0.6, and performed HWE 
tests for the top SNPs from the association analysis.
GWAS was conducted in the three studies (NSS1, NSS2 and PPDS) separately within each 
of the three ancestral groups (EUR, AFR, LAT) and then meta-analyzed within ancestry 
group across studies, and then across ancestral groups and studies. We report fixed-effects 
models as our primary analysis in the Results. Meta-analysis was conducted using an inverse 
variance-weighted fixed effects model in PLINK. A p-value < 5 × 10−8 was used as the 
threshold for genome-wide significance whereas results at p-value < 1 × 10−6 are reported as 
genome-wide suggestive.
We used LDSR33 implemented on LD Hub (http://ldsc.broadinstitute.org)26 to test the 
genetic correlation between insomnia disorder and several other traits in European samples 
using publicly available meta-analytic GWAS for two sleep phenotypes (morningness and 
sleep duration),20 two mental disorders frequently comorbid with insomnia (major 
depression and bipolar disorder),37, 38 a personality trait frequently associated with insomnia 
(neuroticism),39 and subjective well-being.40 We also extended this inquiry to two physical 
traits that have been frequently epidemiologically associated with insomnia, namely Type 2 
diabetes41 and coronary artery disease.42
We performed gene-based tests and pathway analysis using software MAGMA43 and 
FUMA.44 The gene-based test can provide association tests for each gene (N = 18,194) by 
aggregating the SNPs within the gene region and the pathway analysis can identify enriched 
association signals of insomnia disorder in gene sets aggregated in biological pathways. We 
used the final meta-analysis in EUR samples and the 1000 Genomes Project European LD 
reference for this analysis. For the gene-based analysis, we used a combined mean and top 
SNP association model. We used curated pathways and GO terms obtained from MsigDB 
with a total of 10894 pathways. The significance level after Bonferroni correction according 
to the genes or pathways tested is 0.05/18194 = 2.75×10−6 for the gene-based tests and 
0.05/10894 = 4.59×10−6 for the pathway analysis. Additional analyses for functional eQTLs 
were conducted using the Broad GTEx database (https://www.gtexportal.org).45
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RESULTS
SNP-based heritability of Insomnia Disorder
We estimated SNP-based heritability (h2g) using GCTA.34 We found significant h2g 
estimates of 0.115 (se 0.033) for insomnia disorder from the EUR meta-analysis across 
studies (p = 1.78 ×10−4). With LDSR,33 which uses GWAS summary statistics and often 
provides a lower estimate of heritability than GCTA, we found a significant h2g estimate of 
0.078 (se 0.026, p = 0.003). This latter estimate is similar to the most recently available 
LDSR-derived heritability estimate from N = 336,965 EUR individuals for the continuous 
insomnia symptoms (never/sometimes/usually) variable in UK Biobank (h2g = 0.061, se = 
0.0037, p = 5.15 ×10−62) (https://nealelab.github.io/UKBB_ldsc/index.html; last updated 
9-20-2017). (All estimates reported above are on the observed scale; estimates for insomnia 
disorder on the liability scale are all higher, given a population prevalence of 0.10 or higher.)
Genome-wide Association Analyses
Within-Ancestry Cross-Study Meta-analyses
EUR ancestry: In the meta-analysis of EUR ancestry individuals across the three studies we 
observed several genome-wide significant SNPs on Chr7 (q11.22) (top SNP rs147549871, 
OR = 0.538, p = 4.90×10−9) in an intergenic region (Supplementary Figure 4), and several 
genome-wide suggestive SNPs on Chr 9 (top SNP rs7855172, OR = 0.72, p = 9.54×10−8) in 
RFX3. These and other genome-wide suggestive loci are shown in Table 2a.
To test whether the SNPs identified as associated with insomnia were better accounted for 
by major depression, which frequently has insomnia as a prominent symptom, we conducted 
the meta-analyses of our largest ancestral group (EUR) across the three studies also 
adjusting for lifetime major depressive disorder (MDD). These analyses resulted in only 
very modest attenuation of the GWAS signals associated with insomnia disorder, with 
multiple SNPs on Chr7 (q11.22) remaining genome-wide significant (top SNP rs147549871, 
OR = 0.536, p = 1.91×10−8).
AFR ancestry: In the meta-analysis of AFR ancestry individuals across the three studies we 
observed a genome-wide significant SNP on Chr 12 (rs7138947, OR = 3.15, p = 1.92×10−8) 
in NTF3 (Supplementary Figure 5), and a genome-wide suggestive SNP on Chr 3 
(rs185334926, OR = 4.38, p = 4.70×10−7) in CACNA1D (Supplementary Figure 6). These 
and other genome-wide suggestive loci are shown in Table 2b.
LAT ancestry: In the meta-analysis of LAT ancestry individuals across the three studies we 
observed a genome-wide suggestive SNP on Chr 9 (rs35796756, OR = 2.89, p = 8.33×10−7) 
in the intronic region of DEC1. Additional genome-wide suggestive loci are shown in Table 
2c.
Summary statistics for all the top SNPs across ancestral groups are shown in Supplementary 
Tables 3a–5c.
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Trans-Ethnic Cross-Study Meta-Analysis—Several SNPs in a region on Chr7 
(q11.22) (top SNP rs186736700, OR = 0.607, p= 4.88×10−9) were genome-wide 
significantly associated with insomnia disorder in the pan-ancestral meta-analysis across the 
3 studies (Table 3 and Figures 1 and 2). Polygenic risk scores derived from insomnia 
disorder in NSS1+NSS2 were significantly associated with insomnia disorder in PPDS 
(optimal p-value cutoff = 0.05, R2 = 0.00028, p = 0.0048, N SNPS = 41,566).
Comparison with UK Biobank Sleep Disturbance and Insomnia Symptom 
GWAS Findings—We did not observe in our EUR data any association between SNPs 
recently significantly associated with insomnia in UK Biobank GWASs of sleep disturbance 
traits21 or insomnia complaints22. However, in our trans-ethnic meta-analysis, we observed 
nominal association of the UK Biobank genome-wide significant or suggestive results for 
sleep duration21 including rs1380703 on Chr 2 (p = 0.032; where the longer sleep duration 
effect allele in the UK Biobank Study is associated with greater odds of insomnia in our 
study), and rs1456031 (p = 0.036) and rs10953765 (p = 0.051) on Chr 7 (where the shorter 
sleep duration effect allele in the UK Biobank Study is associated with greater odds of 
insomnia in our study).
Gene-based and Pathway Analysis
There are 2 significant genes identified via genome-wide gene-association study (GWGAS) 
with MAGMA after Bonferroni correction for multiple testing. RFX3 (Regulatory Factor 
X3; gene ID 5591), on chromosome 9, with a p-value = 7.61×10−7 obtained by aggregating 
738 SNPs in the region. C1orf100 (chromosome 1 open reading frame 100; gene ID 
200159), on chromosome 1, with a p-value = 1.8×10−6. We list the top 10 genes with the 
most significant p-values from NSS and PPDS EUR samples in Supplementary Table 1. 
There is no overlap of these genes in our EUR group with those significantly associated with 
insomnia complaints in the UK Biobank study that also used MAGMA.22 However, one of 
our top two most significant (p = 6.85E-05) genes, RFX3 (Figure 3 and Supplementary 
Table 6), was nominally associated (p = 0.002) with UK Biobank insomnia severity.22
The pathway enrichment analysis did not identify any significant pathway. We listed the top 
10 pathways from NSS and PPDS European samples meta-analyses in Supplementary Table 
7.
Genetic Correlations
LDSR: Insomnia disorder was significantly – and positively – genetically correlated with 
major depressive disorder (rg = 0.44, se = 0.22, p = 0.047) and type 2 diabetes (rg = 0.43, se 
= 0.20, p = 0.037), but not with bipolar disorder (rg = −0.21, se = 0.22, p = 0.35), 
neuroticism (rg = 0.280, se = 0.32, p = 0.38), sleep duration (rg = −0.045, se = 0.181, p = 
0.80), body mass index (rg = 0.051, se = 0.125, p = 0.68), or coronary artery disease (rg = 
0.016, se = 0.158, p = 0.92). Insomnia disorder was also significantly negatively genetically 
correlated with morningness chronotype (rg = −0.34, se = 0.17, p = 0.039) and subjective 
well-being (rg = −0.588, se = 0.23, p = 0.009) (Table 4). These correlations were uncorrected 
for multiple tests.
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UK Biobank Insomnia Sleep Disturbance: We calculated genetic correlations in 
Europeans between our insomnia disorder and UK Biobank sleep disturbance phenotypes.21 
We found that insomnia disorder in our study and insomnia in the UK Biobank study were 
significantly genetically correlated (rg = 0.305 (se 0.153), p = 0.046) (Table 4). Neither UK 
Biobank sleep duration nor excessive daytime sleepiness phenotypes were significantly 
genetically correlated with insomnia disorder in our study.
We also determined the extent to which the most recently available UK Biobank polygenic 
risk score (PRS) for insomnia – derived from their continuous sleeplessness/insomnia 
severity variable, phenotype #1200 in the UK Biobank GWAS Manifest (https://
docs.google.com/spreadsheets/d/1b3oGI2lUt57BcuHttWaZotQcI0-mBRPyZihz87Ms_No/
edit#gid=1209628142) -- was associated with insomnia disorder in the STARRS dataset. 
Results are shown in Supplementary Figure 7 where it can be seen that the UKBiobank PRS 
for sleepless/insomnia was significantly associated with STARRS insomnia disorder, with 
the strongest association seen at a p-value threshold of p = 0.1 with OR = 1.09 [95% CI 
1.04–1.14] involving 75,123 SNPs.
DISCUSSION
Insomnia is associated with substantial deleterious effects on mental and physical health and 
quality of life.1, 6 This study is one of the largest GWAS of a phenotype approximating 
DSM-5 insomnia disorder conducted to date. As anticipated by twin studies, we confirmed 
evidence of significant heritability of insomnia disorder using genotype data. Furthermore, 
consistent with the observation from twin studies that insomnia and major depression share 
common genetic variance,46 using LDSR we found evidence in our EUR samples of a strong 
and statistically significant positive genetic correlation between insomnia in our study and 
major depression based on GWAS summary statistics from the Psychiatric Genomics 
Consortium.37 Nonetheless, the genetic association with insomnia is distinct and not 
explained fully by MDD since covarying for lifetime MDD had only a modest impact on the 
strength of this association. We also found evidence of a strong and statistically significant 
positive genetic correlation between insomnia in our study and type 2 diabetes.41 This latter 
finding, which was also seen in recent UK Biobank analyses,22 suggests that at least some of 
the phenotypic association (or “risk”) of insomnia and type 2 diabetes is accounted for by 
shared genetic factors. Interestingly, a recent publication from the CHARGE consortium 
documented a genetic correlation between sleep duration and type 2 diabetes, although it 
was longer sleep duration that was associated with increased type 2 diabetes risk.47 We also 
found a strong negative genetic correlation between insomnia disorder and subjective well-
being, a finding that may speak to shared diatheses for the strong relationship between sleep 
disturbance and reduced quality of life.
Our strongest association with insomnia disorder, with a haploblock on Chr 7 (q11.22) 
located in an intergenic region, is approximately 1MB away from the nearest gene (TYW1). 
Nearby on Chr 7 (q11.22) is also AUTS2, a gene previously associated with alcohol 
consumption,48 disorders of which are frequently complicated by insomnia.49 Among the 
other regions implicated in our study are several potentially interesting candidate genes 
and/or eQTLs with links to brain development and sleep related phenotypes. RFX3, 
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identified as statistically significant in our GWGAS, is a transcription factor involved in 
development of brain white matter tracts including corpus callosum50 and thalamocortical 
tract.50, 51 Of potential interest, the thalamocortical tract serves an essential function to 
coordinate oscillating electrical signals across the brain during sleep.52 RFX3 (which, it 
should be noted, was also a gene nominally associated with insomnia complaints in the UK 
BIobank GWGAS)22 was identified in the Broad GTEx database as an eQTL associated 
with the expression of CARM1P1, a nearby gene on chromosome 9. This indicates the 
associated SNPs may be functional, but could perhaps act on genes other than RFX3. NTF3 
is a neurotrophic factor involved in cortical development53 and synaptogenesis.54 DEC1 is a 
circadian clock modulator previously shown to be induced by sleep deprivation.55, 56 A 
genetic homologue of DEC1, DEC2 has been linked to short sleep phenotypes in humans 
and model organisms57. ANO6 is a membrane bound, non-selective cation channel. The 
insomnia associated SNP rs74081827 on Chr 12 (p = 6.86E-07) is located within the 3′ 
UTR of this gene and is an eQTL associated with ANO6 expression. Of potential interest, a 
similar gene on Chr 19, ANO8 was identified in the gene-based analysis (Table S1), and 
elsewhere on Chr 12, ANO2 is immediately adjacent to NTF3 that harbors an insomnia 
associated SNP among AFR subjects. CACNA1D is an L-type calcium channel gene, 
previously associated with a variety of other conditions including bipolar disorder58, 59 
(itself almost invariably associated with sleep disturbance) and cardiometabolic disease.60 A 
functionally similar L-type calcium channel gene, CACNA1C was previously linked with 
sleep latency,18 and both CACNA1C and CACNA1D were reported in a genomic pathway 
analyses to contribute to sleep duration.61 In addition, the T-type calcium channel gene 
CACNA1I, previously associated with schizophrenia, mediates sleep spindles, a 
thalamocortical oscillation in stage 2 sleep that also appears to be an endophenotype of 
schizophrenia.62 Of note, however, our pathway analyses did not highlight a role for calcium 
channel genes overall.
Our study differs methodologically in several important ways from the recent UK Biobank 
Studies of sleep disturbance traits21 and insomnia complaints, respectively.22 The former 
used a one-question phenotype for insomnia symptoms (“Do you have trouble falling asleep 
at night or do you wake up in the middle of the night” with responses “never/rarely,” 
“sometimes,” “usually,” and “prefer not to answer”) and dichotomized individuals into 
controls “never/rarely’” versus cases “usually,” with the middle category (“sometimes”) 
excluded. It did not specify a time frame (i.e., recent versus remote) or duration, nor did it 
ascertain the extent to which the insomnia symptoms were associated with disability or 
distress. Our study more closely approximated lifetime DSM-5 insomnia disorder criteria 
(without ruling out other sleep disorders or other causes of insomnia) in requiring a specific 
number and type of symptoms over a minimal duration. In this regard, our phenotype is 
more similar to the other recent UK Biobank publication that used insomnia complaints to 
categorize patients as cases or controls,22 but the questions used to arrive at this 
determination are quite different from our study, making attempts at true replication 
impossible. In the general population, women suffer insomnia at higher rates than men and 
onset is often associated with physical problems of aging. Accordingly, insomnia has higher 
prevalence in older adults, and especially women. These are two groups that are 
underrepresented in the STARRS samples that consist primarily of young men, but 
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overrepresented in the UK Biobank sample.63 Similarly, the UK Biobank subjects tend to be 
healthier than the general population, 63 whereas STARRS insomnia subjects are enriched 
for risk of psychiatric disorders. As such, in important ways, our results are not directly 
comparable to these other recent analyses. Whereas the several genetic risk loci shared 
across studies and the finding of a significant genetic correlation for insomnia across studies 
likely speak to the common genetic features, the newly reported loci revealed in our study of 
an earlier onset, younger population may confer risk for distinct features of insomnia.
Our results should be interpreted in light of several additional limitations. First, samples 
sizes – especially within ancestral groups – are insufficiently powered to detect many loci of 
modest effect. Second, the insomnia disorder phenotype is defined on the basis of self-report 
only. Accordingly, we are unable to distinguish between different types or causes of 
insomnia. Third, our sample is mostly male. It may be that the genetic factors influencing 
insomnia vary by sex, but we lacked the power to test this hypothesis. Fourth, the present 
study of insomnia disorder constitutes analysis of a secondary trait (i.e., it was not the basis 
for initial ascertainment and selection of subjects for genotyping) and is therefore subject to 
possible bias or imprecision in the estimated effect sizes.64 Fifth, the publicly available 
external GWAS datasets to which we had access consisted solely of individuals of European 
descent, and therefore the conclusions we have drawn regarding genetic correlations may not 
generalize to other ancestry groups.
In summary, this set of genome-wide association studies confirms the heritability of 
insomnia and reveals candidate risk loci. We also find evidence of genetic correlation 
between insomnia disorder and other psychiatric (e.g., major depressive disorder) and 
physical (e.g., type 2 diabetes) disorders, suggesting a shared genetic diathesis for these 
commonly co-occurring phenotypes that recapitulates similar conclusions from prior twin46 
and GWAS47 studies, respectively. Additionally, several of the variants identified rest 
comfortably among loci and pathways already known to be related to sleep and circadian 
rhythms. Taken together, these results provide insights into the possible molecular bases for 
insomnia and related conditions and may inform the development of novel therapeutic 
targets.23–25
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Figure 1. 
Manhattan plot (and Q-Q plot, inset) of NSS1, NSS2, and PPDS trans-ethnic meta-analysis 
genome-wide association study (GWAS)
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Figure 2. 
Locus-zoom plot showing region on Chr 7 containing the genome-wide significant markers 
in the NSS1, NSS2, and PPDS trans-ethnic meta-analysis
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Figure 3. 
Manhattan plot (and Q-Q plot, inset) of NSS1, NSS2, and PPDS combined dataset genome-
wide gene-association study (GWGAS)
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Table 4
LDSR determination of genetic correlation in EUR subjects of Insomnia Disorder with other traits (from 
external study meta-analyses with PubMed ID [PMID] shown)
Phenotype PMID rg SE (rg) p
Major depressive disorder 22472876 0.44 0.22 0.047
Bipolar disorder 21926972 −0.21 0.22 0.351
Neuroticism 24828478 0.28 0.32 0.380
Sleep Duration 27494321 −0.05 0.18 0.802
Body Mass Index 20935630 0.05 0.13 0.683
Coronary Artery Disease 26343387 0.02 0.16 0.917
Type 2 Diabetes 22885922 0.43 0.20 0.037
Chronotype (Morningness) 27494321 −0.34 0.17 0.039
Subjective Well Being 27089181 −0.59 0.23 0.0091
Insomnia 27992416 0.31 0.15 0.046
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